275 related articles for article (PubMed ID: 11074355)
21. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Hoover J; Cole HW; Yao W; Jee WS; Sato M
Endocrinology; 2003 May; 144(5):2008-15. PubMed ID: 12697709
[TBL] [Abstract][Full Text] [Related]
22. Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050).
Luo S; Labrie C; Bélanger A; Candas B; Labrie F
Breast Cancer Res Treat; 1998 May; 49(1):1-11. PubMed ID: 9694606
[TBL] [Abstract][Full Text] [Related]
23. Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation.
Li B; Yu S
Biol Pharm Bull; 2003 Jun; 26(6):780-6. PubMed ID: 12808286
[TBL] [Abstract][Full Text] [Related]
24. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study.
Chen HK; Ke HZ; Jee WS; Ma YF; Pirie CM; Simmons HA; Thompson DD
J Bone Miner Res; 1995 Aug; 10(8):1256-62. PubMed ID: 8585430
[TBL] [Abstract][Full Text] [Related]
25. Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice.
Luo S; Sourla A; Labrie C; Gauthier S; Merand Y; Belanger A; Labrie F
Endocrinology; 1998 May; 139(5):2645-56. PubMed ID: 9564882
[TBL] [Abstract][Full Text] [Related]
26. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
27. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Evans G; Bryant HU; Magee D; Sato M; Turner RT
Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
[TBL] [Abstract][Full Text] [Related]
28. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
[TBL] [Abstract][Full Text] [Related]
29. Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat.
Luo S; Sourla A; Labrie C; Bélanger A; Labrie F
Endocrinology; 1997 Oct; 138(10):4435-44. PubMed ID: 9322961
[TBL] [Abstract][Full Text] [Related]
30. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
31. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats.
Komm BS; Vlasseros F; Samadfam R; Chouinard L; Smith SY
Bone; 2011 Sep; 49(3):376-86. PubMed ID: 21658483
[TBL] [Abstract][Full Text] [Related]
32. Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Iwamoto J; Takeda T; Sato Y; Shen CL; Yeh JK
Exp Anim; 2006 Oct; 55(5):457-66. PubMed ID: 17090962
[TBL] [Abstract][Full Text] [Related]
33. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
[TBL] [Abstract][Full Text] [Related]
34. Effect of clodronate treatment on established bone loss in ovariectomized rats.
Kippo K; Hannuniemi R; Laurén L; Peng Z; Kuurtamo P; Virtamo T; Isaksson P; Osterman T; Väänänen HK; Sellman R
Bone; 1998 Oct; 23(4):333-42. PubMed ID: 9763145
[TBL] [Abstract][Full Text] [Related]
35. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
Sato M; Bryant HU; Iversen P; Helterbrand J; Smietana F; Bemis K; Higgs R; Turner CH; Owan I; Takano Y; Burr DB
J Pharmacol Exp Ther; 1996 Oct; 279(1):298-305. PubMed ID: 8859007
[TBL] [Abstract][Full Text] [Related]
36. [Effect of cyclooxygenase-2 on bone loss in ovariectomized rats].
Guo Y; Zhang CY; Tian Y; DI JM; Qin S
Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):458-62. PubMed ID: 22932114
[TBL] [Abstract][Full Text] [Related]
37. Hesperidin inhibits ovariectomized-induced osteopenia and shows differential effects on bone mass and strength in young and adult intact rats.
Horcajada MN; Habauzit V; Trzeciakiewicz A; Morand C; Gil-Izquierdo A; Mardon J; Lebecque P; Davicco MJ; Chee WS; Coxam V; Offord E
J Appl Physiol (1985); 2008 Mar; 104(3):648-54. PubMed ID: 18174393
[TBL] [Abstract][Full Text] [Related]
38. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Sato M; Rippy MK; Bryant HU
FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
[TBL] [Abstract][Full Text] [Related]
39. A protective effect of Curcuma comosa Roxb. on bone loss in estrogen deficient mice.
Weerachayaphorn J; Chuncharunee A; Mahagita C; Lewchalermwongse B; Suksamrarn A; Piyachaturawat P
J Ethnopharmacol; 2011 Sep; 137(2):956-62. PubMed ID: 21762769
[TBL] [Abstract][Full Text] [Related]
40. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
